CEP-9722
- Generic Name
- CEP-9722
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H26N4O3
- CAS Number
- 916574-83-9
- Unique Ingredient Identifier
- B68083E4YG
- Background
CEP-9722 is under investigation in clinical trial NCT01345357 (Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma).
- Associated Conditions
- -
- Associated Therapies
- -
Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-05-02
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 24
- Registration Number
- NCT01345357
- Locations
- ๐ซ๐ท
Teva Investigational Site 1, Nantes, France
๐ซ๐ทTeva Investigational Site 2, Villejuif, France
๐ง๐ชTeva Investigational Site 3, Bruxelles, Belgium
Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors
- First Posted Date
- 2011-03-09
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT01311713
- Locations
- ๐บ๐ธ
Teva Investigational Site 4, Saint Louis, Missouri, United States
๐บ๐ธTeva Investigational Site 1, Aurora, Colorado, United States
๐บ๐ธTeva Investigational Site 2, Philadelphia, Pennsylvania, United States
Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2012-08-16
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 26
- Registration Number
- NCT00920595
- Locations
- ๐ฌ๐ง
Cephalon Investigational Site, Newcastle upon Tyne, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2024. All Rights Reserved by MedPath